Raju Mohan Purchases 261,752 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan purchased 261,752 shares of the stock in a transaction dated Monday, November 25th. The shares were acquired at an average cost of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the acquisition, the chief executive officer now directly owns 2,175,028 shares of the company’s stock, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Raju Mohan also recently made the following trade(s):

• On Friday, November 22nd, Raju Mohan bought 238,248 shares of Ventyx Biosciences stock. The stock was bought at an average price of $1.83 per share, with a total value of $435,993.84.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $2.54 on Wednesday. The firm has a market cap of $179.60 million, a price-to-earnings ratio of -1.08 and a beta of 0.37. Ventyx Biosciences, Inc. has a 1 year low of $1.67 and a 1 year high of $11.48. The firm’s 50 day moving average price is $2.19 and its two-hundred day moving average price is $2.61.

Analyst Ratings Changes

VTYX has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their price target on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reissued a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a research note on Monday, November 11th. Finally, Canaccord Genuity Group decreased their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Institutional Investors Weigh In On Ventyx Biosciences

Several large investors have recently modified their holdings of VTYX. China Universal Asset Management Co. Ltd. raised its position in shares of Ventyx Biosciences by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after buying an additional 7,096 shares during the period. State Street Corp lifted its stake in Ventyx Biosciences by 0.8% during the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock valued at $2,589,000 after buying an additional 9,783 shares in the last quarter. Palumbo Wealth Management LLC acquired a new position in shares of Ventyx Biosciences in the third quarter worth about $26,000. Finally, SG Americas Securities LLC purchased a new position in shares of Ventyx Biosciences in the second quarter worth approximately $32,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.